(Clonidine + naltrexone) is under clinical development by Allodynic Therapeutics and currently in Phase I for Pain. According to GlobalData, Phase I drugs for Pain have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Clonidine + naltrexone)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Clonidine + naltrexone) overview

ATNC-05, a fixed dose combination of clonidine and naltrexone is under development for the treatment of chronic low back pain, emotional pain, and for the prevention of acute migraine. The combination therapy is administered orally. It acts by targeting alpha 2 adrenergic receptor, and toll like receptor 4. It was also under development for the treatment of trigerminal and postherpetic neuralgia.

For a complete picture of (Clonidine + naltrexone)’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.